Versanis vet Pruzanski becomes Abcuro’s chair

Abcuro Inc., which is investigating whether depleting specific sets of cytotoxic T cells can treat a rare muscle-wasting disease and other immunological indications, appointed Mark Pruzanski as chair. Pruzanski founded and was CEO of Intercept Pharmaceuticals Inc., then chairman and CEO of Versanis Bio Inc. until its acquisition by Eli Lilly and Co. (NYSE:LLY). 

Cancer and fibrosis company Alentis Therapeutics AG hired Rizwan Velji as CBO. Velji was managing director at William Blair, Citigroup and Lazard. Alentis raised a $105 million series C round in April, led by Jeito Capital. ...